Login to Your Account

Pharma: Other News To Note

Wednesday, December 12, 2012
• Eisai Inc., of Woodcliff Lake, N.J., said the FDA determined that the company has met the agency's written request requirements for pediatric exclusivity for Aciphex (rabreprazole sodium). As a result, Eisai now has gained an additional six months of U.S. market exclusivity for Aciphex, which will expire on Nov. 8, 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription